Simpson, Julie A. and Agbenyega, Tsiri and Barnes, Karen I. and Di Perri, Gianni and Folb, Peter and Gomes, Melba and Krishna, Sanjeev and Krudsood, Srivicha and Looareesuwan, Sornchai and Mansor, Sharif and McIlleron, Helen and Miller, Raymond and Molyneux, Malcolm and Mwenechanya, James and Navaratnam, Visweswaran and Nosten, Francois and Olliaro, Piero and Pang, Lorrin and Ribeiro, Isabela and Tembo, Madalitso and van Vugt, Michele and Ward, Steve and Weerasuriya, Kris and Win, Kyaw and White, Nicholas J. (2006) Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. PLoS MEDICINE, 3 (11). pp. 2113-2123. ISSN 1549-1277
Available under License Creative Commons Attribution.
Background Intra-rectal artesunate has been developed as a potentially life-saving treatment of severe malaria in rural village settings where administration of parenteral antimalarial drugs is not possible. We studied the population pharmacokinetics of intra-rectal artesunate and the relationship with parasitological responses in patients with moderately severe falciparum malaria. Methods and Findings Adults and children in Africa and Southeast Asia with moderately severe malaria were recruited in two Phase II studies (12 adults from Southeast Asia and 11 children from Africa) with intensive sampling protocols, and three Phase III studies (44 children from Southeast Asia, and 86 children and 26 adults from Africa) with sparse sampling. All patients received 10 mg/kg artesunate as a single intra-rectal dose of suppositories. Venous blood samples were taken during a period of 24 h following dosing. Plasma artesunate and dihydroartemisinin (DHA, the main biologically active metabolite) concentrations were measured by high-performance liquid chromatography with electrochemical detection. The pharmacokinetic properties of DHA were determined using nonlinear mixed-effects modelling. Artesunate is rapidly hydrolysed in vivo to DHA, and this contributes the majority of antimalarial activity. For DHA, a one-compartment model assuming complete conversion from artesunate and first-order appearance and elimination kinetics gave the best fit to the data. The mean population estimate of apparent clearance (CL/F) was 2.64 (l/kg/ h) with 66% inter-individual variability. The apparent volume of distribution (V/F) was 2.75 (l/kg) with 96% inter-individual variability. The estimated DHA population mean elimination half-life was 43 min. Gender was associated with increased mean CL/F by 1.14 (95% CI: 0.36–1.92) (l/kg/h) for a male compared with a female, and weight was positively associated with V/F. Larger V/Fs were observed for the patients requiring early rescue treatment compared with the remainder, independent of any confounders. No associations between the parasitological responses and the posterior individual estimates of V/F, CL/F, and AUC0–6h were observed. Conclusions The pharmacokinetic properties of DHA were affected only by gender and body weight. Patients with the lowest area under the DHA concentration curve did not have slower parasite clearance, suggesting that rectal artesunate is well absorbed in most patients with moderately severe malaria. However, a number of modelling assumptions were required due to the large intra- and inter-individual variability of the DHA concentrations.
|Additional Information:||Published: November 28, 2006. Citation: Simpson JA, Agbenyega T, Barnes KI, Di Perri G, Folb P, et al. (2006) Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. PLoS Med 3(11): e444. doi:10.1371/journal. pmed.0030444|
|Uncontrolled Keywords:||ACUTE FALCIPARUM-MALARIA; ORAL ARTESUNATE; ARTEMISININ SUPPOSITORIES; UNCOMPLICATED MALARIA; CLINICAL EFFICACY; CHILDREN; BIOAVAILABILITY; QUININE; ARTEMETHER; ACID|
|Subjects:||R Medicine > R Medicine (General)|
|Divisions:||?? sch_tropmed ??|
|Depositing User:||Adina Dudau|
|Date Deposited:||24 Jul 2008 08:58|
|Last Modified:||09 Oct 2014 11:15|
Actions (login required)